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CC BY-NC-ND license (http://creativeAbstract Objective: Used extensively to treat cardiovascular disease, Danqi analogous for-
mulas (DQAF) include prescriptions for Danqi (DQ), Fufang Danshen (FFDS) and Qishen Yiqi
(QSYQ). Differences in prescription compatibility result in varying emphases of DQAF in clinical
application.
Methods and results: Based on network analysis in this study, common and distinct mechanisms
of DQAF actions on cardiovascular disease were analyzed at a systemic level. Components
etargetsepathways models were developed by Cytoscape (http://www.cytoscape.org/);
whereby, target information for active compounds was obtained based on the PharmMapper
database (http://59.78.96.61/pharmmapper/), which was further used to search pathways us-
ing the Kyoto Encyclopedia of Genes and Genomes database (http://www.genome.jp/kegg/).
Based on target and network analyses, we discovered RBP4 is a potential common target of
DQAF, while mitogen-activated protein kinase 1 (MAPK1) and glutathione S-transferase P were
potential targets of FFDS and QSYQ, respectively. Furthermore, the potential of DQAF to treat
cardiovascular disease occurs through effects on the endocrine, immune, and digestive sys-
tems, in addition to lipid, sugar and amino acid metabolic pathways. Whereas FFDS exhibits ef-
fects on Toll-like receptor, transforming growth factor beta and MAPK signaling pathways; QSYQ
exerts effects on cyclic adenosine monophosphate signaling, as well as metabolism of gluta-
thione and arachidonic acid.0 84738661.
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Network analysis of Danqi analogous formulas 117Table 1 DQAF composition.
Formula Composition
DQ Salvia miltiorrhiza, Pa
FFDS Salvia miltiorrhiza, Pa
borneolum
QSYQ Salvia miltiorrhiza, Pa
Dalbergia odorifera, A
Note: DQ stands for Danqi formula
Danshen formula, QSYQ stands for QConclusion: This study not only reflects the formulas-effect modality of multiple compounds,
targets and pathways, but also provides clues to better understand physiological mechanisms
of DQAF.
ª 2016 Beijing University of Chinese Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Traditional Chinese Medicine (TCM) has been recognized as
a typical representative of complementary and alternative
medicine.1 Using prescriptions called “formulas”, clinical
applications of TCM advocate combinatory therapeutic
strategies. In contrast to modern pharmacology, which
often focuses upon a single chemical entity, TCM formulas
can affect multiple therapeutic targets to produce a syn-
ergistic effect resulting from multiple ingredients.2,3 In TCM
theory, analogous formulas (AF) refer to series of similar
prescriptions based on common herb pairs. Elucidating
mechanisms of AF is significant to clarify principles for
rational use, with significant emphasis on applicable in-
dications and prevention of misuse. Network analysis has
provided methodologies and opportunities to reveal
mechanisms of action for TCM formulas based on complex
biological systems present in the human body.4
Danqi analogous formulas (DQAF), a series of pre-
scriptions primarily derived from the herb pair Salvia mil-
tiorrhiza and Panax notoginseng, include prescriptions for
Danqi (DQ), Fufang Danshen (FFDS) and Qishen Yiqi (QSYQ).
The basic formula of DQAF is DQ, which consists of S. mil-
tiorrhiza and P. notoginseng. Different emphases of DQAF
in clinical applications arise from their varied composition,
as shown in Table 1. DQAF are commonly prescribed to
treat cardiovascular disease, the leading health problem
worldwide.5 However, many previous studies have only
investigated the effects of a single DQAF composition. For
example, FFDS was found to protect myocardial ischemia
and reperfusion injury though the Akt-eNOS signaling
pathway6; whereas, QSYQ was found to inhibit platelet
aggregation.7 Most of these studies have elucidated one or
several pharmacological effects of a specific formula,
providing the foundation for further study of common and
distinct mechanisms of DQAF.
In this study, a network analysis approach was employed
to analyze active mechanisms of DQAF. Based on Pharm-
Mapper (http://59.78.96.61/pharmmapper/) and Kyoto




, FFDS stands for Fufang
ishen Yiqi formula.genome.jp/kegg/) databases, targets and pathways infor-
mation for active compounds was obtained. Subsequently,
componentsetargetsepathways network models of DQAF
were constructed by Cytoscape (http://www.cytoscape.
org/).8 Potential targets and pathways that were common
and distinct to DQAF were then evaluated using network
model analysis. Our study aimed to provide new clues to
better understand mechanisms of DQAF actions, in a
concerted effort to instruct rational application of antibi-
otics and reflect the formulas-effect modality of multiple
compounds, targets and pathways.
Methods and experimental section
Target-mining of DQAF’s main active components
As the compositions of TCM formulas are complex, it is
impossible to study all of the components and reliably
separate results. Based on literature retrieval and accord-
ing to principles defining the main ingredient for efficacy as
having a high content and entering the blood, the main
active components of DQAF were selected to clarify com-
mon and distinctive mechanisms.
Information for targets of the main active components of
DQAF was extracted from PharmMapper,9 an updated
platform for potential target identification integrating
pharmacophore with statistical methods. PharmMapper
automatically identifies the best mapping poses of query
molecules against all pharmacophore models in its Pharm-
TargetDB, a pharmacophore database annotated from all
the target information in BindingDB, TargetBank, DrugBank
and potential drug target databases, including over 7000
receptor-based pharmacophore models.
Analysis of the compoundsetargetsepathways
network of DQAF
The pathway annotation of targets was performed based on
the KEGG database, developed to facilitate understanding
of high-level functions and utilities of biological systems
from molecular-level information.10
Information regarding compounds, targets and pathways
was collected to construct a compoundsetargetsepath-
ways network model using Cytoscape, a standard tool for
visualization and integrated analysis of biological networks.
In graphical networks, nodes represent compounds, protein
targets and pathways; whereas, edges encode com-
poundetarget or targetepathway interactions. Based on
such network analysis, common and distinct pathways of
DQAF and the formulas-effect modality of multiple com-
pounds, targets and pathways may be evaluated.
Table 2 Common and distinct active components of each DQAF.
Formulas Common active components Distinguished active components
DQ Tanshinone IIA, cryptotanshinone, salianolic acid A,
salvianolic acid B, tanshinol, protocatechuic aldehyde,




QSYQ Butein, formononetin, isoliquiritigenin,
nerolidol, calycosin, astragaloside and
astragaloside22e27
Note: DQ stands for Danqi formula, FFDS stands for Fufang Danshen formula, QSYQ stands for Qishen Yiqi formula.
Table 3 Potential targets of the main active components of DQAF.
UniProt Targets Frequency UniProt Targets Frequency UniProt Targets Frequency
Danqi prescription
P02753 RBP4 4 P10276 RARA 1 Q06520 SULT2A1 1
P01112 HRAS 4 P08581 METa 1 P50225 SULT1A1 1
P09211 GSTP1a 4 P36873 PPP1CCa 1 P04035 HMGCRa 1
Q16539 MAPK14 3 P08254 MMP3 1 P49841 GSK3B 1
Q6P3U7 RXRAa 3 A4QPA9 MAP2K1a 1 Q03518 TAP1 1
P18031 PTPN1a 3 P00918 CA2 1 P54278 PMS2 1
P28845 HSD11B1a 3 Q92731 ESR2 1 O15540 FABP7 1
P35398 RORAa 2 Q86UC5 RARB 1 P14555 PLA2G2A 1
P49888 SULT1E1 2 P00734 F2 1 P42574 CASP3 1
P15121 AKR1B1 2 Q2VPJ6 HSP90AA1 1 P10275 ARa 1
P35968 KDRa 2 P05230 FGF1 1 P06730 EIF4Ea 1
O00204 SULT2B1 2 P13716 ALAD 1 P29218 IMPA1 1
P53355 DAPK1 2 Q06187 BTKa 1 Q3KQS6 MMEa 1
P12931 SRC 2 P11413 G6PD 1 P11309 PIM1 1
P27338 MAOBa 2 Q6FGU2 DTYMK 1 Q86WY9 INSR 1
Fufang Danshen prescription
P28482 MAPK1 3 P10275 ARa 2 P28845 HSD11B1a 2
P35398 RORAa 2 A4QPA9 MAP2K1a 2 P27487 DPP4 1
Qishen Yiqi prescription
P09211 GSTP1a 9 Q04609 FOLH1 2 P06730 EIF4Ea 1
P18031 PTPN1a 4 Q6IRT1 ADH5 1 P27338 MAOBa 1
Q3KQS6 MMEa 4 Q06187 BTKa 1 P14061 HSD17B1 1
Q6P3U7 RXRAa 3 P10827 THRA 1 P11712 CYP2C9 1
P36873 PPP1CCa 3 P0CG30 GSTT2B 1 P34896 SHMT1 1
P10275 ARa 3 P06744 GPI 1 P08581 METa 1
O60760 HPGDS 3 P23368 ME2 1 P04035 HMGCRa 1
P08246 ELANE 2 P02679 FGG 1 P35968 KDRa 1
a The targets of analogous formulas are the same as the targets of DQ.
Table 4 Information of potential targets from main active components of DQAFs.
Related pathways Number of pathways Related pathways Number of pathways
Human diseases 49 Nervous system 7
Signaling pathway 19 Amino acid metabolism 7
Endocrine system 15 Digestive system 5
Cellular processes 11 Genetic information processing 5
Immune system 10 Xenobiotics biodegradation 2
Carbohydrate metabolism 8 Sensory system 1
Lipid metabolism 7 Circulatory system 2
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Figure 1 Componentsetargetsepathways network model of major active compounds of DQ. Note: Triangles represent active ingredients. Circles represent target proteins.






























120 S. Zheng et al.Results and discussion
Analysis of targets for active components
Through literature retrieval, primary common and distinct
active components of each DQAF were obtained, as shown
in Table 2.
Potential targets of the main active components of each
DQAF are shown in Table 3. In addition, 10 DQ compounds
interacted with 45 targets, two distinct FFDS compounds
interacted with six targets, and 7 distinct QSYQ compounds
interacted with 24 targets.
The results of our target prediction suggested that pri-
mary targets of DQ are retinol binding protein 4 (RBP4),
GTPase HRas (HRAS), glutathione S-transferase P (GSTP1),
whose frequencies are high. These targets canFigure 2 Componentsetargetsepathways network model of maj
ingredients. Circles represent target proteins. Hexagons represent
FFDS has a greater effect. SP: signaling pathway.simultaneously interact with multiple components to elicit
a synergistic effect and enhance efficacy; thus, the higher
frequency of the target, the more important it is to some
extent. Among such targets is RBP4, an adipokine secreted
primarily by liver and adipose tissue.28 Li et al, demon-
strated RBP4 is a novel risk factor for cardiovascular disease
in patients with hyperinsulinemia and coronary artery dis-
ease.29 Meanwhile, a study by Lambadiari et al, related
serum RBP4 levels to the presence and severity of coronary
artery disease.30 This indicates RBP4 may be a potential
target of DQ and other DQAF, as DQ is the basis for all DQAF.
Primary potential targets of other DQAF had different
emphases. Mitogen-activated protein kinase 1 (MAPK1),
also called ERK2,31 was the primary target of FFDS;
whereas, the primary target of QSYQ was glutathione S-
transferase P (GSTP1). MAPK1 is a reported mediator ofor active compounds of FFDS. Note: Triangles represent active
pathways, with gray hexagons representing pathways for which
Network analysis of Danqi analogous formulas 121estrogen action, which plays an important role in protect-
ing pre-menopausal women from cardiovascular disease.32
In addition, thrombin exhibits important effects on endo-
thelial dysfunction in cardiovascular disease by activating
MAPK1.33 Therefore, MAPK1 plays a significant role in car-
diovascular disease and the effect of FFDS may be related.
GSTP1 is a member of the glutathione S-transferase (GST)
family, which participates in metabolic detoxification of
various environmental carcinogens. Specific genetic poly-
morphisms within GSTs have been reported to influence
individual susceptibility to various pathologies, including
cardiovascular disease.34 As such, benefits of QSYQ for the
treatment of cardiovascular disease may relate to media-
tion of GSTP1 polymorphisms.Figure 3 Componentsetargetsepathways network model of maj
ingredients. Circles represent target proteins. Hexagons represent
QSYQ has greater effects. SP: signaling pathway.Analysis of the compoundsetargetsepathways
network of DQAF
Based on KEGG pathway mapping, annotation of DQ targets
included 148 related pathways, as shown in Table 4. The
related compoundsetargetsepathways network model
constructed by Cytoscape is shown in Fig. 1.
DQ and other DQAF treat cardiovascular disease by
mediating different pathways involved in various systems
including the endocrine, immune, and digestive systems, as
well as lipid, sugar and amino acid metabolic pathways.
This network showed a clear three-level structure of the
action modes of primary DQAF compounds, in which mul-
tiple compounds regulated multiple pathways byor active compounds of QSYQ. Note: Triangles represent active
pathways, with gray hexagons representing pathways for which
122 S. Zheng et al.modulating groups of targets (and their associated path-
ways), which indicated their potential effects for treating
cardiovascular disease.
As shown in Fig. 2, FFDS had a greater effect on Toll-like
receptor, TGF-b and MAPK signaling pathways, which were
not included in the network of QSYQ. Toll-like receptors,
including TLR1, TLR2, TLR3, and TLR4, are a class of pro-
teins that play a significant role in the innate immune sys-
tem. In particular, TLR4 has been shown to mediate
maladaptive left ventricular remodeling and damage of
cardiac function after myocardial infarction.35 Toll-like
receptor signaling is also reported to be a key modulator
of cardiac cell survival and ischemic injury.36 TGF-b
signaling has also been associated with cardiovascular dis-
ease, whereby complex regulation of TGF-b translates to a
critical role in cardiovascular physiology, as TGF-b1
signaling appears to be deregulated in associated disorders
such as atherosclerotic vascular disease.37 Moreover, the
MAPK signaling pathway has been reported to play a sig-
nificant role in treating cardiovascular disease.38,39 This
indicates FFDS may exert its primary effects on cardiovas-
cular disease through mediation of Toll-like receptor, TGF-b
and MAPK signaling pathways.
QSYQ had greater effects on cyclic adenosine mono-
phosphate (cAMP) signaling, and metabolism of gluta-
thione and arachidonic acid (Fig. 3); glutathione and
arachidonic acid metabolism were not included in FFDS.
cAMP signaling pathways have been shown to exert
inhibitory effects on pro-inflammatory cytokines, such as
IL-6, which are strongly associated with coronary heart
disease.40 A previous report suggested antiplatelet-
aggregation effects of QSYQ were related to improve-
ment of cAMP metabolism.41 Hence, this feature proved
the accuracy of our network model to some extent.
Glutathione and arachidonic acid metabolism have also
been demonstrated to play critical roles in cardiovascular
disease.42,43 Therefore, it is suggested the primary effects
of QSYQ for treating cardiovascular disease are associated
with the cAMP signaling pathway and metabolism of
glutathione and/or arachidonic acid.Conclusions
In summary, RBP4 is potentially a common target of DQAF;
whereas, MAPK1 is a potential target of FFDS and GSTP1 is a
potential target of QSYQ. As such, DQAF treat cardiovas-
cular disease through effects on endocrine, immune, and
digestive systems, as well as lipid, sugar and amino acid
metabolic pathways. While FFDS exhibited effects on Toll-
like receptors, TGF-b and MAPK signaling pathways, QSYQ
exerted effects on cAMP signaling and metabolism of
glutathione and arachidonic acid. DQAF not only had com-
mon targets and pathways, but also displayed a specific
emphasis to treat cardiovascular diseases by modulating
groups of targets and a number of associated pathways.
This reflected the formulas-effect modality of multiples
compounds, targets and pathways. Although further “wet”
experiments are needed to validate these conclusions, our
results may provide clues to a faster and better under-
standing of DQAF mechanisms of action than what currently
exists. Taking into consideration the complexity of TCManalogous formulas, our model also provides guidance for
further exploration.Funding
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